369 related articles for article (PubMed ID: 25373133)
1. Recognizing and overcoming potential barriers to oral medications for MS.
Moses H
J Clin Psychiatry; 2014 Oct; 75(10):e28. PubMed ID: 25373133
[TBL] [Abstract][Full Text] [Related]
2. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.
Thomas RH; Wakefield RA
Am J Health Syst Pharm; 2015 Jan; 72(1):25-38. PubMed ID: 25511835
[TBL] [Abstract][Full Text] [Related]
3. In the coming year we should abandon interferons and glatiramer acetate as first-line therapy for MS: yes.
Fox RJ
Mult Scler; 2013 Jan; 19(1):24-5. PubMed ID: 23303880
[No Abstract] [Full Text] [Related]
4. Oral treatment for multiple sclerosis.
Killestein J; Rudick RA; Polman CH
Lancet Neurol; 2011 Nov; 10(11):1026-34. PubMed ID: 22014437
[TBL] [Abstract][Full Text] [Related]
5. [Oral treatments in multiple sclerosis].
Meca-Lallana JE; Hernández-Clares R; Carreón-Guarnizo E
Med Clin (Barc); 2014 Dec; 143 Suppl 3():23-9. PubMed ID: 25732946
[TBL] [Abstract][Full Text] [Related]
6. A review of safety-related pregnancy data surrounding the oral disease-modifying drugs for multiple sclerosis.
Lu E; Wang BW; Alwan S; Synnes A; Dahlgren L; Sadovnick AD; Tremlett H
CNS Drugs; 2014 Feb; 28(2):89-94. PubMed ID: 24343726
[TBL] [Abstract][Full Text] [Related]
7. Emerging oral drugs for multiple sclerosis.
Gasperini C; Cefaro LA; Borriello G; Tosto G; Prosperini L; Pozzilli C
Expert Opin Emerg Drugs; 2008 Sep; 13(3):465-77. PubMed ID: 18764723
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis.
Wiese MD; Rowland A; Polasek TM; Sorich MJ; O'Doherty C
Expert Opin Drug Metab Toxicol; 2013 Aug; 9(8):1025-35. PubMed ID: 23682862
[TBL] [Abstract][Full Text] [Related]
9. Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved.
Gold R
CNS Drugs; 2011 Jan; 25(1):37-52. PubMed ID: 21128693
[TBL] [Abstract][Full Text] [Related]
10. Oral fingolimod (gilenya) for multiple sclerosis.
Med Lett Drugs Ther; 2010 Dec; 52(1353-1354):98-9. PubMed ID: 21344782
[No Abstract] [Full Text] [Related]
11. Delayed fingolimod-associated asystole.
Espinosa PS; Berger JR
Mult Scler; 2011 Nov; 17(11):1387-9. PubMed ID: 21652609
[TBL] [Abstract][Full Text] [Related]
12. [Oral disease-modifying agents in relapsing-remitting multiple sclerosis].
Iljicsov A; Pál Z; Simó M
Neuropsychopharmacol Hung; 2015 Dec; 17(4):197-205. PubMed ID: 26727724
[TBL] [Abstract][Full Text] [Related]
13. Drugs: An injection of hope.
Graham-Rowe D
Nature; 2012 Apr; 484(7393):S4. PubMed ID: 22509505
[No Abstract] [Full Text] [Related]
14. [Two new oral disease modifying therapies in relapsing remitting multiple sclerosis].
Lebrun C; de Seze J
Rev Neurol (Paris); 2014 Dec; 170(12):721-2. PubMed ID: 25487772
[No Abstract] [Full Text] [Related]
15. The future of multiple sclerosis therapy.
Kieseier BC; Wiendl H; Hartung HP; Stüve O
Pharmacol Res; 2009 Oct; 60(4):207-11. PubMed ID: 19717009
[TBL] [Abstract][Full Text] [Related]
16. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.
Singer B; Ross AP; Tobias K
Int J Clin Pract; 2011 Aug; 65(8):887-95. PubMed ID: 21679286
[TBL] [Abstract][Full Text] [Related]
17. Fingolimod for multiple sclerosis.
Drug Ther Bull; 2012 Feb; 50(2):18-20. PubMed ID: 22329953
[TBL] [Abstract][Full Text] [Related]
18. What's new about oral treatments in Multiple Sclerosis? Immunogenetics still under question.
Pistono C; Osera C; Boiocchi C; Mallucci G; Cuccia M; Bergamaschi R; Pascale A
Pharmacol Res; 2017 Jun; 120():279-293. PubMed ID: 28396093
[TBL] [Abstract][Full Text] [Related]
19. Background and rationale for mechanism of action, efficacy, and safety of fingolimod (Gilenya), the first oral therapy for remitting-relapsing multiple sclerosis: with special emphasis upon visual safety.
Huggins A; Sergott RC
Curr Opin Ophthalmol; 2011 Nov; 22(6):447-50. PubMed ID: 21946305
[No Abstract] [Full Text] [Related]
20. Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis.
Guarnera C; Bramanti P; Mazzon E
Drug Des Devel Ther; 2017; 11():2193-2207. PubMed ID: 28814828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
